Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P1080: ZANUBRUTINIB PLUS OBINU...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Bibliographic Details
Main Authors: Judith Trotman, Pier Luigi Zinzani, Jiri Mayer, Chris Flowers, Fontanet Bijou, Ana Carla Oliveira, Kamal Bouabdallah, Rod Johnson, Alejandro Martin Garcia-Sancho, Mariano Provencio Pulla, Marek Trneny, Hervé Tilly, Wojciech Jurczak, Elena Ivanova, Pil Kim, Adam Greenbaum, Sha Huang, Richard Delarue, Rebecca Auer
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000971216.26871.31
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000971216.26871.31

Similar Items

  • S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL
    by: P. L. Zinzani, et al.
    Published: (2022-06-01)
  • Disseminated Enteroviral Infection Associated with Obinutuzumab
    by: Claire Dendle, et al.
    Published: (2015-09-01)
  • P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
    by: J. P. Sharman, et al.
    Published: (2022-06-01)
  • Research advances of obinutuzumab in the treatment of membranous nephropathy
    by: Xiao-jing Lin, et al.
    Published: (2024-01-01)
  • Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
    by: Supreet Sethi, et al.
    Published: (2020-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs